Diabetes Mellitus
|
0.500 |
Biomarker
|
group |
BEFREE |
Obesity rats induced by 8-week high fat diet (HFD) were randomly divided into obesity group (OB) and exercised obesity group (EOB) with 8 rats each group, and 40 diabetes rats established by 8-week HFD plus low dose of streptozotocin were randomly divided into 4 groups: diabetes group (DM), exercised diabetes group (EDM), exercised diabetes plus PPARγ agonist pioglitazone group (EDP), and exercised diabetes plus PPARγ antagonist GW9662 group (EDG).
|
30873215 |
2019 |
Diabetes Mellitus
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Interestingly, it also modulated the expression of peroxisome proliferator-activated receptor γ (PPARγ) and pancreatic and duodenal homeobox 1 (PDX-1).Our findings showed that <i>A. annulatum</i> and its bioactive compounds are capable of improving insulin secretion by pancreatic β-cells.This suggests that <i>A. annulatum</i> can be used as a therapeutic agent to treat diabetes.
|
31382473 |
2019 |
Diabetes Mellitus
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Loss-of-function mutations in PPARG result in familial partial lipodystrophy subtype 3 (FPDL3), a rare condition characterized by aberrant adipose tissue distribution and severe metabolic complications, including diabetes.
|
30595551 |
2019 |
Diabetes Mellitus
|
0.500 |
Biomarker
|
group |
BEFREE |
We utilized this 3D co-culture system to screen PPARγ antagonists that might have potential as therapeutic agents for diabetes as demonstrated by an in vivo assay.
|
30609258 |
2019 |
Diabetes Mellitus
|
0.500 |
Biomarker
|
group |
BEFREE |
Synthetic PPAR ligands are widely used in the treatment of dyslipidemia (e.g. fibrates - PPARα activators) or in diabetes mellitus (e.g. thiazolidinediones - PPARγ agonists) while a new generation of dual agonists reveals hypolipemic, hypotensive, antiatherogenic, anti-inflammatory and anticoagulant action.
|
31161987 |
2019 |
Diabetes Mellitus
|
0.500 |
Biomarker
|
group |
BEFREE |
The thiazolidinedione (TZD) class of Peroxisome proliferator-activated receptor gamma agonists has restricted clinical use for diabetes mellitus due to fluid retention and potential cardiovascular risks.
|
31087547 |
2019 |
Diabetes Mellitus
|
0.500 |
Biomarker
|
group |
BEFREE |
Silenced CHOP protects pancreatic B-cell function by targeting peroxisome proliferator-activated receptor-γ coactivator-1α through nuclear factor-κB signaling pathway in diabetes mellitus.
|
30848505 |
2019 |
Diabetes Mellitus
|
0.500 |
Biomarker
|
group |
BEFREE |
The peroxisome proliferator‑activated receptor γ (PPARγ) agonist pioglitazone has been widely used in previous studies to ameliorate diabetes mellitus and regulate inflammation.
|
30816473 |
2019 |
Diabetes Mellitus
|
0.500 |
Biomarker
|
group |
BEFREE |
Peroxisome Proliferator-Activated Receptor γ (PPARγ) is an important sensor at the crossroad of diabetes, obesity, immunity and cancer as it regulates adipogenesis, metabolism, inflammation and proliferation.
|
30931956 |
2019 |
Diabetes Mellitus
|
0.500 |
Biomarker
|
group |
BEFREE |
We aim to review the therapeutic significance of PPARγ for ailments other than diabetes and highlight natural molecules with potential PPARγ agonistic activity.
|
31131751 |
2019 |
Diabetes Mellitus
|
0.500 |
Biomarker
|
group |
BEFREE |
Peroxisome proliferator-activated receptor gamma (PPARγ) has been implicated in the pathology of numerous diseases involving diabetes, stroke, cancer, or obesity.
|
28975471 |
2018 |
Diabetes Mellitus
|
0.500 |
Biomarker
|
group |
BEFREE |
Hence, the results conclude inhibition of PPARγ by the bioactive compounds from Faba bean, which may provide insights into developing future therapeutic molecules for diabetes mellitus.
|
29923224 |
2018 |
Diabetes Mellitus
|
0.500 |
Biomarker
|
group |
BEFREE |
Pioglitazone, a ligand of PPARγ, is used to treat diabetes and possesses anti-inflammatory properties.
|
29222347 |
2018 |
Diabetes Mellitus
|
0.500 |
Biomarker
|
group |
BEFREE |
These results suggested that AGP plays a significant role in the initiation/progression of diabetes-related atherosclerosis through PPARγ activation.
|
29355589 |
2018 |
Diabetes Mellitus
|
0.500 |
Biomarker
|
group |
BEFREE |
Time-dependent therapeutic roles of nitazoxanide on high-fat diet/streptozotocin-induced diabetes in rats: effects on hepatic peroxisome proliferator-activated receptor-gamma receptors.
|
29244961 |
2018 |
Diabetes Mellitus
|
0.500 |
Biomarker
|
group |
BEFREE |
We prospectively enrolled multi-centre ESRD patients of Han Chinese origin between 2002 and 2003, recording their antioxidant (superoxide dismutase [SOD2], glutathione peroxidase [GPX1]) and peroxisome proliferator activated receptor-γ (PPAR-γ) genotyping results, and stratified based on DM.
|
27925431 |
2018 |
Diabetes Mellitus
|
0.500 |
Biomarker
|
group |
BEFREE |
Beetle (Ulomoides dermestoides) fat improves diabetes: effect on liver and pancreatic architecture and on PPARγ expression.
|
29694509 |
2018 |
Diabetes Mellitus
|
0.500 |
Biomarker
|
group |
BEFREE |
Targeting PPAR-γ and its downstream mitochondrial enzymes will provide novel strategies in preventing metabolic and myocardial dysfunction in diabetes mellitus.
|
30048968 |
2018 |
Diabetes Mellitus
|
0.500 |
Biomarker
|
group |
BEFREE |
Peroxisome proliferator-activated receptor-γ (PPARγ) is a master regulator of adipogenesis and a target of the thiazolidinedione (TZD) class of antidiabetic drugs; therefore, identifying novel regulators of PPARγ action in adipocytes is essential for the future development of therapeutics for diabetes.
|
30121577 |
2018 |
Diabetes Mellitus
|
0.500 |
Biomarker
|
group |
BEFREE |
The advanced development of PPARγ agonists represents a valuable research tool for diabetes therapy.
|
29473866 |
2018 |
Diabetes Mellitus
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Beneficial effects of exercise training and chamomile flowers extract (CFE) are shown through activation of PPARγ, which is a promising drug target in diabetes and associated with GPC-4 synthesis.
|
29948407 |
2018 |
Diabetes Mellitus
|
0.500 |
Biomarker
|
group |
BEFREE |
Pioglitazone (Piog) activates peroxisome proliferator activated receptor-γ (PPARγ) and is widely used in clinic for the treatment of diabetes mellitus.
|
29221940 |
2018 |
Diabetes Mellitus
|
0.500 |
Biomarker
|
group |
BEFREE |
Supplementation with polyunsaturated fatty acids in pregnant rats with mild diabetes normalizes placental PPARγ and mTOR signaling in female offspring developing gestational diabetes.
|
29190548 |
2018 |
Diabetes Mellitus
|
0.500 |
Biomarker
|
group |
BEFREE |
Peroxisome proliferator-activated receptor γ (PPARγ) is involved in the pathology of numerous diseases including atherosclerosis, diabetes, obesity, and cancer.
|
29628981 |
2018 |
Diabetes Mellitus
|
0.500 |
Biomarker
|
group |
BEFREE |
Pioglitazone is a PPARγ agonist commonly prescribed for the clinical treatment of diabetes.
|
27993834 |
2017 |